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Background: Despite the curative potential of SCT for pediatric
ALL, relapse remains the most frequent cause of treatment failure.
Management of relapse after SCT is complicated by drug resistance,
limited utility of DLI, treatment-related toxicities, and GVHD.
Moxetumomab pasudotox (MP) is a recombinant anti-CD22 immu-
notoxin with properties that warrant evaluation in the peritransplant
setting. Cytotoxicity is mediated by targeted inhibition of protein
synthesis in CD22+ cells, an antigen expressed on most B-lineage
ALL blasts, and no immune effector cells are required for activity.
Methods: A pediatric phase I trial of MP is being conducted for
CD22+ hematologic malignancies (ClinicalTrials.gov
NCT00659425). Doses are administered at 5-40 mg/kg IV QODx6
every 21 days. An initial cohort (A) included 1 patient each at the first
3 dose levels followed by standard 3+3 dose escalation starting at 30
mg/kg. In an attempt to prevent capillary leak syndrome (CLS), an
ongoing cohort (B) receives dexamethasone around MP doses.
Results: 23 patients have been treated to date. The most common
drug-related adverse events (AEs) were mild, reversible increased
weight, transaminase elevation, and hypoalbuminemia. Treatment
was discontinued in 1 patient after dose 1 due to ALL-related com-
plications. Dose-limiting CLS was observed in 2 patients in Cohort
A (30 mg/kg; grade 3 and 4, deemed drug-related serious AEs) and in
no patients in Cohort B. 1 patient treated at 40 mg/kg developed re-
fractory hypercalcemia, that was possibly drug-related, and died of
cardiac arrhythmia during central venous catheter placement. That
dose level (5B) was expanded and is accruing. 12 of 23 patients had
prior SCT for ALL. Time from SCT to relapse was 3-12 mos (me-
dian, 9) and from SCT to treatment withMP was 4-34 mos (median,
13). 9 of 12 patients who had previously undergone SCTwere evalu-
able for response. 3 (33%) patients had complete responses (CR) and
4 (44%) had hematological activity (.50% blast reduction and/or
improvement in neutrophil/platelet counts). 1 patient with a CR
confirmed by flow cytometry proceeded to 2nd SCT.
Conclusions:MP is active in relapsed pediatric ALL after SCT.No-
tably, 3 of 4 CRs observed so far on this trial have been in patients
treated for post-transplant relapse. The observed antileukemic activ-
ity and safety profile of MP, coupled with its unique properties, war-
rant further study in the peritransplant setting.
This study was sponsored by MedImmune, LLC.
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TREOSULFAN, FLUDARABINE AND ALEMTUZUMAB CONDITIONING FOR
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH
PRIMARY IMMUNODEFICIENCY: UK EXPERIENCE
Slatter, M.1, Rao, K.2, Chiesa, R.2, Amrolia, P.2, Nademi, Z.1, Flood, T.1,
Abinun, M.1, Cant, A.1, Hambleton, S.1, Goulden, N.2, Davies, G.2,
Qasim, W.2, Gaspar, H.B.2, Gennery, A.1, Veys, P.2 1Newcastle upon
Tyne Hospital NHS Foundation Trust, Newcastle upon Tyne, United
Kingdom; 2Great Ormond Street Hospital NHS Trust, London, United
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Ninety-eight children received Treosulfan 42g/m2 or 36g/m2 (\1
year), Fludarabine 150mg/m2 with Alemtuzumab (in most), prior to
Hematopoietic Cell Transplantation (HCT) for Primary Immuno-
deficiency (PID) or Severe Immune Dysregulation between 2004
and July 2011.
Median age at transplant was 10 months (range: 1.4 to 191); 55%
patients were 12 months or younger. Donors were: unrelated (79), of
which 28 were cord blood (CB), matched sibling donors (3), other
matched family donors (13), haploidentical donors (3). Stem cellsource was: PBSC (39), BM (31), CB (28). Median follow up was
18.5 months (range: 2 to 82).
Overall survival was 85%. Of the 15 deaths, 8 patients had HLH
many of whom were not in remission at the time of HCT. There
was no VOD and no toxicity related deaths. Eighteen % had
GVHD, only 7% . grade II. One patient rejected their graft; 35
of 55 (64%) more than 1 year post transplantation had 100% donor
chimerism in all cell lineages. Increased use of PBSC favoured im-
proved donor myeloid chimerism and with the use of Alemtuzumab
the incidence of significant GVHDwas not increased. High levels of
donor chimerism are of particular importance in diseases such as
Wiskott Aldrich Syndrome and Chronic Granulomatous Disease.
Long-term follow up is required to determine the gonadotoxic ef-
fects of this approach in comparison to Busulfan containing regi-
mens, but the combination of Treosulfan, Fludarabine and
Alemtuzumab is an ideal choice of conditioning forHCT in PID, as-
sociated with good lymphoid and myeloid engraftment and low reg-
imen related toxicity.86
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Background:Childhoodmyelodysplastic syndrome (MDS) is a rare,
heterogeneous disorder that is clinically distinct from adult MDS.
Hematopoietic stem cell transplant (HSCT) is the treatment of
choice, but there is no consensus regarding patient, disease, or treat-
ment-related factors that predict outcomes after HSCT.
Materials andMethods:Weperformed a retrospective review of 37
consecutive pediatric patients who received allogeneic HSCT for
MDS at the University of Minnesota Amplatz Children’s Hospital
between 1990 and 2010.
Table. Patient Characteristics
Total (%)Total Patients 37
Gender
Male 18 (49%)
Female 19 (51%)
Median Age at Diagnosis 11 (range 1-21)
Year of HSCT
1990-1999 24 (65%)
2000-2010 13 (35%)
Time from Diagnosis to HSCT (days)
<140 18 (49%)
$140 19 (51%)
Type of MDS
Primary 20 (54%)
Secondary 17 (46%)
Blast Count Pre-HSCT
<5% 27 (73%)
$5% 10 (27%)
Cytogenetics*
Monosomy 7 21 (57%)
Trisomy 8 7 (19%)
Normal/Other 8 (22%)
MDS Classification
RC 30 (81%)
RAEB 7 (19%)
IPSS Risk
Low 1 (3%)
Int-1 15 (40%)
Int-2 21 (57%)
Pre-HSCT Chemotherapy(Continued )
